Navigation Links
Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
Date:2/5/2009

ending the results of the ongoing Phase 2 trial.

AT2220 (1-deoxynojirimycin HCl) for the treatment of Pompe Disease

Amicus continued to make progress throughout the fourth quarter with its ongoing Phase 2 clinical trial of AT2220 in adult Pompe patients. The trial includes an 11-week treatment period with an optional extension study. The objectives of the trial include the evaluation of the safety and pharmacodynamics of multiple doses and regimens of AT2220. The results of this study are expected to be available in the second half of 2009.

In addition, Amicus is continuing to conduct preclinical animal studies to evaluate the effects of administering AT2220 in combination with ERT. Results announced at the American Society of Human Genetics conference in November 2008 indicate that AT2220 in combination with ERT has the potential to increase the stability and tissue uptake of ERT. Amicus is conducting additional preclinical proof-of-concept studies to determine the feasibility of a combination that may be appropriate for Pompe patients who are not amenable to chaperone monotherapy. Amicus expects to discuss additional results at relevant scientific conferences during 2009.

Preclinical Chaperone Programs

Amicus continues to invest in research and development to assess the potential for applying its versatile chaperone technology platform to the treatment of a broader range of human genetic diseases. As part of this effort, Amicus continues to conduct preclinical studies in Parkinson's disease and is investing in new research aimed at evaluating disease targets for other neurodegenerative and genetic disorders.

2009 Financial Guidance

In 2009, Amicus expects to report approximately $70 million in operating expenses, which it expects to be offset by approximately $50 million in program cost-sharing reimbursements and clinical mil
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
2. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
3. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
4. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
5. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
6. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
7. Amicus Therapeutics Opens Research Facility in San Diego
8. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
9. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
10. Amicus Therapeutics Announces First Quarter 2008 Financial Results
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)...  The Paul G. Allen Family Foundation announced today ... six groups of researchers with projects at the frontier ... growing mature human brain cells in the laboratory. The ... over three years.  "This new cohort ... significant because the field of neuronal maturation is at ...
(Date:4/30/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a ... medicine, today announced that it will release first quarter ... after the close of the U.S. financial markets. The ... Thursday, May 7, 2015 at 4:30 p.m. Eastern / ... corporate developments. For both "listen-only" participants and ...
(Date:4/30/2015)... , April 30, 2015 WuXi PharmaTech (Cayman) ... a leading global contract R&D services provider, today announced ... non-binding proposal letter, dated April 29, 2015, from a ... (the "Chairman"), founder, chairman and chief executive officer ... ("ABG") that proposes a transaction (the "Transaction") involving the ...
(Date:4/30/2015)... SAINT-MALO, FRANCE (PRWEB) April 30, 2015 ... States and at http://www.lespausa.com , Phytomer’s ... to sensitive and reactive skin while battling the ... inflammation. This restorative cream is formulated with star ... derived via biotechnology in a complex of soothing ...
Breaking Biology Technology:The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 3WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 3
... computational tools and a state-of-the-art scanning transmission electron ... Iowa State University materials science and engineering researchers ... solid metallic materials known as metallic glasses. ... Review Letters , the findings fill a gap ...
... Richard Dolinar, chairman of the Alliance for Safe Biologic ... U.S. Food and Drug Administration (FDA) should resolve before ... in prepared testimony for the FDA,s May 11th public ... for the development of biosimilar products. ...
... May 10, 2012 Aviir Diagnostic Laboratory has entered ... as a participating provider with Stratose Network and their ... Stratose A true pioneer of claims ... PlanCare America, 4MOST Health, Qualident and KeyClaims) works to ...
Cached Biology Technology:In metallic glasses, researchers find a few new atomic structures 2In metallic glasses, researchers find a few new atomic structures 3Alliance for Safe Biologic Medicines Chairman Urges FDA to Ensure that Patient Safety is the Cornerstone of Biosimilar Pathway 2Aviir Laboratories Announce National Agreement with Stratose 2Aviir Laboratories Announce National Agreement with Stratose 3
(Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the ... Business Report" report to their offering. This report ... Thousands by the following Segments: Face Biometrics, and Voice Biometrics. The ... , Japan , Europe ... & Africa , and Latin ...
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
(Date:3/23/2015)... March 23, 2015   HOYOS Labs , a ... today announced that the Company will demonstrate multiple biometrics-based ... and consumers at Connect:ID on March 23 through 25, ... Labs will highlight the IEEE Biometric Open Protocol Standard; ... and enterprise access control system. BOPS was invented by ...
Breaking Biology News(10 mins):Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... of the Midwest is expected to result in the second-smallest ... to a University of Michigan forecast released today. The ... zone of about 1,200 square miles, an area the size ... replace 2000 (1,696 square miles) as the year with the ...
... the University of Calgary have developed a way for ... colour, face shape or fingerprintsand create a learning system ... from different sources. Marina Gavrilova, the founding head ... to introduce and study neural network based models for ...
... proteins by the Department of Biotechnology of Neiker-Tecnalia have ... tumor cell lines. This property shows that the latex ... easily acclimated, could be considered in clinical trials for ... has been done in collaboration with the University of ...
Cached Biology News:U-M forecasters predict second-smallest Gulf of Mexico 'dead zone' 2U-M forecasters predict second-smallest Gulf of Mexico 'dead zone' 3U-M forecasters predict second-smallest Gulf of Mexico 'dead zone' 4Researchers advance biometric security 2Neiker-Tecnalia identifies antitumour proteins in the latex of the plant Euphorbia trigona 2